Compare Cenovus Energy Inc (CVE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Novavax Inc — how do they compare? Cenovus Energy Inc trades at $30.29 (market cap $55.00B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Cenovus Energy Inc is far larger — about 42× Novavax Inc's market cap, and Cenovus Energy Inc pays a 2.09% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| CVE | NVAX | |
|---|---|---|
Market Cap | $55.00B | $1.31B |
Sector | Energy | Health |
52-Week High | $31.80 | $11.19 |
52-Week Low | $14.83 | $6.22 |
Enterprise Value | $61.08B | $889.30M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.2, up 2.17% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, matching estimates with $1.11 EPS, and raised full-year production guidance. Valuation ratios appear attractive with a P/E of 11.56 and EV/EBITDA of 5.77, while profitability remains solid with an 11.48% net income margin and 20.96% ROE.
Outlook is positive driven by higher oil prices and record oil sands production, but risks include commodity price volatility and refining margin pressures. Analyst consensus leans bullish with 11 Buy ratings, though geopolitical tensions and Canadian regulations pose headwinds for sustained growth.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
